This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG

This study has been terminated.
(Only 2 patients screened but none of them were enrolled.)
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01820169
First received: March 11, 2013
Last updated: September 2, 2016
Last verified: September 2016
March 11, 2013
September 2, 2016
April 2013
December 2013   (Final data collection date for primary outcome measure)
Improvement in HbA1c in 6 months [ Time Frame: 6 months ]
Same as current
Complete list of historical versions of study NCT01820169 on ClinicalTrials.gov Archive Site
  • 1. Comparison with historical control in HbA1c change. [ Time Frame: Baseline to 6 months ]
  • 2. Change in blood gulucose. [ Time Frame: Baseline to 6 months ]
  • 3. Change in BMI. [ Time Frame: Baseline to 6 months ]
  • 4. Occurance of sever hypoglycemia. [ Time Frame: Baseline to 6 months ]
  • 5. Doctor's opinion for Accu-Chek 360° View. [ Time Frame: Baseline to 6 months ]
Same as current
Not Provided
Not Provided
 
Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG
Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG
This clinical study is to determine if the use of structured testing, which is a blood glucose monitoring, via the Accu-Chek 360° View blood glucose analysis tool has a positive effect on the subjects overall glycemic control.
Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Diabetes
Device: ;Accu-Chek Compact Plus LCM bulk Japan
HbA1c would be changed by more careful control in blood glucose with SMBG.
Experimental: Single arm
Intervention: Device: ;Accu-Chek Compact Plus LCM bulk Japan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
2
December 2013
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

1. Age:= and >20 years. 2. Intend to paticipate in this study after education of structured testing. 3.HbA1c:= and >7.5% in the recect 2 months.

Exclusion Criteria:

1.Pregancy. 2. Heavy complication 3. judged unsuitable by doctor

Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
Not Provided
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT01820169
RD001551
Not Provided
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Principal Investigator: Naoki Sakane National organization Hospital Kyoto Medical Center
Hoffmann-La Roche
September 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP